|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.590 SEK | -0.12% |
|
-4.02% | -36.37% |
| 06-26 | Vivesto Completes Enrollment in Canine Study | FW |
| 06-16 | Vivesto AB Reports Positive Results From Intravenous Cantrixil Pharmacokinetic And Toxicology Study | CI |
| Market Cap | 95.1M 9.79M 8.58M 7.91M 7.41M 13.89M 924M 14.18M 36.8M 456M 36.76M 35.96M 1.58B | P/E 2026 * |
-2.81x | P/E 2027 * | -2.05x |
|---|---|---|---|---|---|
| Enterprise Value | 87.1M 8.97M 7.86M 7.25M 6.78M 12.72M 846M 12.99M 33.7M 418M 33.67M 32.93M 1.45B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | - |
| Free-Float |
56.4% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Vivesto AB
| 1 day | -0.12% | ||
| 1 week | -4.02% | ||
| Current month | -20.02% | ||
| 1 month | -26.08% | ||
| 3 months | +6.05% | ||
| 6 months | -38.29% | ||
| Current year | -36.37% |
| 1 week | 8.44 |  | 9 |
| 1 month | 8.31 | | 11 |
| Current year | 7 | | 19.5 |
| 1 year | 7 | | 31.9 |
| 3 years | 7 | | 90.6 |
| 5 years | 7 | | 319 |
| 10 years | 7 | | 1,670 |
| Manager | Title | Age | Since |
|---|---|---|---|
Erik Kinnman
CEO | Chief Executive Officer | 68 | 23/01/2023 |
Robert Maiorana
DFI | Director of Finance/CFO | 66 | 01/07/2022 |
| Chief Tech/Sci/R&D Officer | 39 | 01/01/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 46 | 25/05/2022 | |
Hege Hellstrom
BRD | Director/Board Member | 61 | 26/09/2019 |
Pål Ryfors
BRD | Director/Board Member | 43 | 25/05/2022 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 25/03/22 | Buy | Chief Executive Officer | 12,200 | 0.0027% | ||
| 24/03/22 | Others | Chairman | 120,000 | 0.0268% | ||
| 20/12/21 | Free | Chief Executive Officer | 2,250,000 | 0.5018% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.12% | -4.02% | -62.41% | -71.27% | 9.79M | |
| +7.13% | +9.97% | +55.80% | +160.09% | 1,077B | |
| +3.99% | +11.50% | +67.09% | +55.96% | 613B | |
| +4.20% | +17.03% | +38.97% | +91.06% | 448B | |
| +0.99% | +4.85% | +28.17% | +23.89% | 332B | |
| +1.82% | +8.19% | +40.04% | +27.95% | 293B | |
| +0.22% | +6.75% | +31.30% | +42.34% | 286B | |
| +0.73% | +8.53% | -27.33% | -39.55% | 215B | |
| +1.56% | +6.14% | +29.30% | +60.97% | 193B | |
| +3.26% | +3.33% | +15.55% | +68.24% | 159B | |
| Average | +2.38% | +6.80% | +21.65% | +41.97% | 361.61B | |
| Weighted average by Cap. | +3.85% | +8.93% | +41.75% | +80.17% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | - |
| Net income | -31M -3.19M -2.8M -2.58M -2.41M -4.53M -301M -4.62M -12M -149M -11.98M -11.72M -516M | -46M -4.74M -4.15M -3.83M -3.58M -6.72M -447M -6.86M -17.8M -221M -17.78M -17.39M -766M |
| Net Debt | -8M -824K -722K -666K -623K -1.17M -77.69M -1.19M -3.1M -38.39M -3.09M -3.02M -133M | -10M -1.03M -903K -832K -779K -1.46M -97.11M -1.49M -3.87M -47.99M -3.87M -3.78M -166M |
Employees
4
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/06/26 | SEK 8.590 | -0.12% | 7,119 |
| 25/06/26 | SEK 8.600 | -3.15% | 4,945 |
| 24/06/26 | SEK 8.880 | -0.22% | 24,582 |
| 23/06/26 | SEK 8.900 | +0.11% | 20,265 |
| 22/06/26 | SEK 8.890 | -0.67% | 10,238 |
Annual profits - Rate of surprise
- Stock Market
- Stocks
- VIVE Stock
Select your edition
All financial news and data tailored to specific country editions
